病例报告：采用不同治疗方法治疗化脓性汗腺炎和银屑病共存。
Case report: Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches.
机构信息
Tzaneio Hospital, Piraeus/Athens, Greece.
Andreas Sygros University Hospital, Athens, 161 21, Greece.
出版信息
F1000Res. 2019 Nov 26;8:2002. doi: 10.12688/f1000research.21216.2. eCollection 2019.
Hidradenitis suppurativa and psoriasis are considered chronic inflammatory diseases suggesting the existence of common pathogenetic pathways. We present two cases of comorbid psoriasis and hidradenitis suppurativa, treated with certolizumab pegol and brodalumab due to failure of response to other conventional therapies. Monoclonal antibody therapies have revolutionized the treatment of chronic inflammatory disorders such as psoriasis and hidradenitis suppurativa. Given the good clinical response to anti-IL-17 and anti-tumor necrosis factor agents in patients undergoing psoriasis and hidradenitis treatment, investigations on this direction could represent the starting point in new therapeutic approach for revolutionary treatment in these difficult-to-treat diseases.
化脓性汗腺炎和银屑病被认为是慢性炎症性疾病，这表明它们存在共同的发病途径。我们报告了两例化脓性汗腺炎和银屑病并存的病例，由于对其他常规治疗反应不佳，这些患者接受了培塞利珠单抗和布罗达umab 治疗。单克隆抗体治疗彻底改变了银屑病和化脓性汗腺炎等慢性炎症性疾病的治疗方法。鉴于在接受银屑病和化脓性汗腺炎治疗的患者中，抗 IL-17 和抗肿瘤坏死因子药物的临床疗效良好，因此针对这一方向的研究可能成为这些难治性疾病革命性治疗的新治疗方法的起点。
Zotero 插件